Michael Linnebacher

List of Publications by Year
in descending order

136	3,956	136950 32	149698 56
papers	citations	h-index	g-index

140	140	140	6192
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers. Gastroenterology, 2008, 134, 988-997.	1.3	319
2	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature Communications, 2015, 6, 7002.	12.8	251
3	Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens. International Journal of Cancer, 2001, 93, 6-11.	5.1	202
4	COX-2 and PPAR-Î³ Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells. Molecular Cancer Therapeutics, 2013, 12, 69-82.	4.1	169
5	Cannabidiol inhibits lung cancer cell invasion and metastasisviaintercellular adhesion moleculeâ€1. FASEB Journal, 2012, 26, 1535-1548.	0.5	138
6	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.9	91
7	Mouse models of colorectal cancer: Past, present and future perspectives. World Journal of Gastroenterology, 2020, 26, 1394-1426.	3.3	89
8	A global assessment of recent trends in gastrointestinal cancer and lifestyleâ€associated risk factors. Cancer Communications, 2021, 41, 1137-1151.	9.2	85
9	Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochemical Pharmacology, 2014, 92, 312-325.	4.4	79
10	Colorectal cancer vaccines: Tumor-associated antigensvsneoantigens. World Journal of Gastroenterology, 2018, 24, 5418-5432.	3.3	77
11	Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer, 2010, 10, 362.	2.6	72
12	MicroRNAâ€“mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromosomes and Cancer, 2015, 54, 129-141.	2.8	70
13	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	7.0	66
14	WT1 is a tumor-associated antigen in colon cancer that can be recognized byin vitro stimulated cytotoxic T cells. International Journal of Cancer, 2004, 109, 385-392.	5.1	65
15	Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immunity, 2004, 4, 14.	3.2	62
16	Tumor-infiltrating B cells. OncoImmunology, 2012, 1, 1186-1188.	4.6	58
17	Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. Journal of Clinical Immunology, 2003, 23, 415-423.	3.8	56
18	AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. PLoS ONE, 2019, 14, e0211644.	2.5	56

#	Article	IF	Citations
19	Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes. Cancer Immunology, Immunotherapy, 2012, 61, 1093-1100.	4.2	55
20	Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. European Journal of Human Genetics, 2006, 14, 561-566.	2.8	53
21	Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes. Oncotarget, 2015, 6, 40095-40111.	1.8	52
22	Arginine deprivation by arginine deiminase ofStreptococcus pyogenescontrols primary glioblastoma growthin vitroandin vivo. Cancer Biology and Therapy, 2015, 16, 1047-1055.	3.4	52
23	Expression of an endogenous retroviral sequence from the HERVâ€H group in gastrointestinal cancers. International Journal of Cancer, 2007, 121, 1417-1423.	5.1	49
24	Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas. PLoS ONE, 2012, 7, e52485.	2.5	49
25	Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. International Journal of Cancer, 2010, 127, 889-898.	5.1	46
26	Î²-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells. Scientific Reports, 2018, 8, 3178.	3.3	45
27	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 6243-6259.	7.0	42
28	Establishment and Characterization of Primary Glioblastoma Cell Lines from Fresh and Frozen Material: A Detailed Comparison. PLoS ONE, 2013, 8, e71070.	2.5	41
29	Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies. Journal of Translational Medicine, 2017, 15, 27.	4.4	41
30	Class I histone deacetylases regulate p53/NF-ÎºB crosstalk in cancer cells. Cellular Signalling, 2017, 29, 218-225.	3.6	41
31	Ex-vivo Clonally Expanded B Lymphocytes Infiltrating Colorectal Carcinoma Are of Mature Immunophenotype and Produce Functional IgG. PLoS ONE, 2012, 7, e32639.	2.5	40
32	Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine, 2006, 24, 2238-2247.	3.8	35
33	Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin. Neoplasia, 2017, 19, 301-309.	5.3	33
34	Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. Journal of Lipid Research, 2013, 54, 3116-3129.	4.2	31
35	Integrated Biobanking and Tumor Model Establishment of Human Colorectal Carcinoma Provides Excellent Tools for Preclinical Research. Cancers, 2019, 11, 1520.	3.7	31
36	The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World Journal of Gastroenterology, 2004, 10, 3583.	3.3	31

#	Article	IF	Citations
37	Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. International Journal of Oncology, 2009, 35, 321-7.	3.3	31
38	Identification of an MSI-H Tumor-Specific Cytotoxic T Cell Epitope Generated by the (<mml:math) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Frame ofU79260(FTO). Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	29
39	The impact of pyrvinium pamoate on colon cancer cell viability. International Journal of Colorectal Disease, 2014, 29, 1189-1198.	2.2	29
40	Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies. European Journal of Cancer, 2013, 49, 2587-2595.	2.8	28
41	Tumor Take Rate Optimization for Colorectal Carcinoma Patient-Derived Xenograft Models. BioMed Research International, 2016, 2016, 1-7.	1.9	28
42	Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-Lymphocyte lines for transfer in patients with renal cell carcinoma. International Journal of Cancer, 2005, 117, 256-264.	5.1	27
43	Human endogenous retroviruses and cancer: Causality and therapeutic possibilities. World Journal of Gastroenterology, 2012, 18, 6027.	3.3	27
44	Establishment and characterization of cell lines from chromosomal instable colorectal cancer. World Journal of Gastroenterology, 2015, 21, 164.	3.3	27
45	Bacterial immunotherapy of gastrointestinal tumors. Langenbeck's Archives of Surgery, 2012, 397, 557-568.	1.9	26
46	Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy. Clinical and Developmental Immunology, 2013, 2013, 1-14.	3.3	26
47	NSG mice as hosts for oncological precision medicine. Laboratory Investigation, 2020, 100, 27-37.	3.7	26
48	Impact of portal branch ligation on tissue regeneration, microcirculatory response and microarchitecture in portal blood-deprived and undeprived liver tissue. Microvascular Research, 2011, 81, 274-280.	2.5	25
49	An MSI Tumor Specific Frameshift Mutation in a Coding Microsatellite of MSH3 Encodes for HLA-A0201-Restricted CD8+ Cytotoxic T Cell Epitopes. PLoS ONE, 2011, 6, e26517.	2.5	25
50	Cancer-Cell-Derived IgG and Its Potential Role in Tumor Development. International Journal of Molecular Sciences, 2021, 22, 11597.	4.1	25
51	Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Therapy, 2000, 7, 1357-1364.	4.6	23
52	Bacteriolytic therapy of experimental pancreatic carcinoma. World Journal of Gastroenterology, 2010, 16, 3546.	3.3	22
53	Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Experimental Hematology, 2010, 38, 1066-1073.	0.4	22
54	CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens. Molecular and Cellular Proteomics, 2021, 20, 100032.	3.8	22

#	Article	IF	Citations
55	Clonality characterization of natural epitope-specific antibodies against the tumor-related antigen topoisomerase IIa by peptide chip and proteome analysis: a pilot study with colorectal carcinoma patient samples. Analytical and Bioanalytical Chemistry, 2012, 403, 227-238.	3.7	20
56	E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts. Neoplasia, 2014, 16, 972-981.	5.3	20
57	Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Oncotarget, 2015, 6, 39342-39356.	1.8	20
58	Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis. Oncotarget, 2014, 5, 4467-4479.	1.8	20
59	Lysates of S. pyogenes Serotype M49 Induce Pancreatic Tumor Growth Delay by Specific and Unspecific Antitumor Immune Responses. Journal of Immunotherapy, 2008, 31, 704-713.	2.4	19
60	Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. Cancer Immunology, Immunotherapy, 2013, 62, 1283-1292.	4.2	19
61	Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells. Oncotarget, 2018, 9, 27835-27850.	1.8	19
62	Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines. BioMed Research International, 2014, 2014, 1-13.	1.9	18
63	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nature Communications, 2018, 9, 2287.	12.8	18
64	Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cellular Immunology, 2011, 269, 120-127.	3.0	17
65	Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma. PLoS ONE, 2018, 13, e0191511.	2.5	17
66	Tumor-infiltrating B cells come into vogue. World Journal of Gastroenterology, 2013, 19, 8.	3.3	17
67	The â€œNorth German Tumor Bank of Colorectal Cancerâ€• status report after the first 2Âyears of support by the German Cancer Aid Foundation. Langenbeck's Archives of Surgery, 2013, 398, 251-258.	1.9	16
68	Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancerâ€”a meta-analysis and current overview. International Journal of Colorectal Disease, 2015, 30, 1015-1028.	2.2	15
69	Deciphering molecular mechanisms of arginine deiminase-based therapy â€“ Comparative response analysis in paired human primary and recurrent glioblastomas. Chemico-Biological Interactions, 2017, 278, 179-188.	4.0	15
70	Mechanistic insights into p53â€regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. Molecular Oncology, 2021, 15, 3404-3429.	4.6	15
71	Colorectal carcinoma tumour budding and podia formation in the xenograft microenvironment. PLoS ONE, 2017, 12, e0186271.	2.5	14
72	Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In Silico Models. Cancers, 2020, 12, 28.	3.7	14

#	Article	IF	Citations
73	Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme. PLoS ONE, 2017, 12, e0185208.	2.5	14
74	Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell responsein vitro andin vivo. , 1999, 83, 547-554.		13
75	Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. European Journal of Cancer, 2006, 42, 981-987.	2.8	13
76	Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repairâ€deficiency and Lynch syndrome. Molecular Carcinogenesis, 2017, 56, 1753-1764.	2.7	13
77	Cellular vaccination of MLH1^{â^'/â^'} mice â€“ an immunotherapeutic proof of concept study. OncoImmunology, 2018, 7, e1408748.	4.6	13
78	Reevaluating the Concept of Treating Experimental Tumors with a Mixed Bacterial Vaccine: Coleyâ€™s Toxin. Clinical and Developmental Immunology, 2012, 2012, 1-16.	3.3	12
79	Generation, Characterization and Application of Antibodies Directed against HERV-H Gag Protein in Colorectal Samples. PLoS ONE, 2016, 11, e0153349.	2.5	12
80	Establishment and characterization of HROC69â€‰â€“â€‰a CrohnÂ´s related colonic carcinoma cell line and its matched patient-derived xenograft. Scientific Reports, 2016, 6, 24671.	3.3	12
81	Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype. PLoS ONE, 2015, 10, e0143194.	2.5	12
82	The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis. Oncotarget, 2016, 7, 53583-53598.	1.8	12
83	Generation of Xenotransplants from Human Cancer Biopsies to Assess Anti-cancer Activities of HDACi. Methods in Molecular Biology, 2017, 1510, 217-229.	0.9	11
84	Human Colorectal Carcinoma Infiltrating B Lymphocytes Are Active Secretors of the Immunoglobulin Isotypes A, G, and M. Cancers, 2019, 11, 776.	3.7	11
85	Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line. World Journal of Gastroenterology, 2018, 24, 3749-3759.	3.3	11
86	PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: Two hits on the gene?. Oncology Reports, 2014, 31, 2236-2244.	2.6	10
87	Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1927-34.	2.3	10
88	Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. Oncotarget, 2017, 8, 69756-69767.	1.8	10
89	Targeting Immune-Related Molecules in Cancer Therapy: A ComprehensiveIn VitroAnalysis on Patient-Derived Tumor Models. BioMed Research International, 2019, 2019, 1-12.	1.9	9
90	Analyzing nonâ€cancer causes of death of colorectal carcinoma patients in the US population for the years 2000â€“2016. Cancer Medicine, 2021, 10, 2740-2751.	2.8	9

#	Article	IF	Citations
91	The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner. Molecular Cancer Therapeutics, 2022, 21, 100-112.	4.1	9
92	Single nucleotide polymorphism array analysis of microsatellite-stable, diploid/near-diploid colorectal carcinomas without the CpG island methylator phenotype. Oncology Letters, 2013, 5, 173-178.	1.8	8
93	Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells. British Journal of Cancer, 2021, 124, 1411-1420.	6.4	8
94	Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study. Future Oncology, 2021, 17, 549-563.	2.4	8
95	Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids In Vitro: A 3D Tumour Model for Pre-therapeutic Drug Screening. Anticancer Research, 2021, 41, 2257-2275.	1.1	8
96	Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Therapy, 2000, 7, 1357-1364.	4.6	8
97	Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress. Cancer & Metabolism, 2022, 10, .	5.0	8
98	Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background. Cancer, 2004, 100, 1978-1986.	4.1	7
99	Induction of an Antitumoral Immune Response by Wild-Type Adeno-Associated Virus Type 2 in an In Vivo Model of Pancreatic Carcinoma. Pancreas, 2007, 35, 63-72.	1.1	7
100	Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma. BMC Immunology, 2011, 12, 38.	2.2	7
101	Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines. World Journal of Gastroenterology, 2018, 24, 4880-4892.	3.3	7
102	Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and MSH2-deficient colorectal tumours and potential mutation carriers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 9-16.	2.8	6
103	Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells. Langenbeck's Archives of Surgery, 2010, 395, 365-371.	1.9	6
104	The EpCAM^{high}/CD44^{high} colorectal carcinoma stem cell phenotype is not preferentially expressed in tumour buds. Histopathology, 2010, 56, 553-555.	2.9	6
105	Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells. International Journal of Oncology, 2012, 40, 764-72.	3.3	6
106	Murine Endogenous Retroviruses Are Detectable in Patient-Derived Xenografts but Not in Patient-Individual Cell Lines of Human Colorectal Cancer. Frontiers in Microbiology, 2018, 9, 789.	3.5	6
107	Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer. Cancers, 2021, 13, 4717.	3.7	6
108	Galvanotactic Migration of Glioblastoma and Brain Metastases Cells. Life, 2022, 12, 580.	2.4	6

#	Article	IF	Citations
109	The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. Cell Biology and Toxicology, 2023, 39, 2401-2419.	5.3	6
110	An In Vitro System for the Determination of Individualized Immunosuppression. Transplantation Proceedings, 2008, 40, 918-920.	0.6	5
111	Combining bacterial-immunotherapy with therapeutic antibodies: A novel therapeutic concept. Vaccine, 2012, 30, 2786-2794.	3.8	5
112	Optimizing the process of nucleofection for professional antigen presenting cells. BMC Research Notes, 2015, 8, 472.	1.4	5
113	Correlation between Kir4.1 expression and barium-sensitive currents in rat and human glioma cell lines. Neuroscience Letters, 2021, 741, 135481.	2.1	5
114	The HROC-Xenobankâ€"A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models. Cancers, 2021, 13, 5882.	3.7	5
115	Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. International Journal of Cancer, 2002, 100, 606-614.	5.1	4
116	Effective Antitumoral Immune Responses Are Not Induced by Cytosine Deaminase Suicide Gene Transfer in a Syngeneic Rat Pancreatic Carcinoma Model. European Surgical Research, 2006, 38, 513-521.	1.3	4
117	Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1425-1431.	2.5	4
118	Microsatellite instability in hematological malignancies. OncoImmunology, 2013, 2, e25419.	4.6	4
119	Creation and Maintenance of a Living Biobank - How We Do It. Journal of Visualized Experiments, 2021, , .	0.3	4
120	Microsatellite Status and Ilºbî± Expression Levels Predict Sensitivity to Pharmaceutical Curcumin in Colorectal Cancer Cells. Cancers, 2022, 14, 1032.	3.7	4
121	Semiallogenic fusions of MSI+tumor cells and activated B cells induce MSI-specific T cell responses. BMC Cancer, 2011, 11, 410.	2.6	3
122	Microdensitometry of osteopontin as an immunohistochemical prognostic biomarker in colorectal carcinoma tissue microarrays: potential and limitations of the method in â€˜biomarker pathologyâ€™. Histopathology, 2012, 61, 823-832.	2.9	3
123	Glucose Influences the Response of Glioblastoma Cells to Temozolomide and Dexamethasone. Cancer Control, 2022, 29, 107327482210754.	1.8	3
124	Patient-individual cancer cell lines and tissue analysis delivers no evidence of sequences from DNA viruses in colorectal cancer cells. BMC Gastroenterology, 2020, 20, 260.	2.0	2
125	Gene Chip Analysis for Detection of Potential Tumor Suppressor Genes in Colorectal Cancer Cell Lines. Gastroenterology, 2011, 140, S-1042.	1.3	1
126	Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2015, 21, 221.	3.3	1

#	Article	IF	Citations
127	A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer. Cancers, 2022, 14, 3252.	3.7	1
128	In vivo adenovirus mediated gene transfer of the Eschericha coli cytosine meaminase gene to pancreatic tumours induces chemosensitivity to 5-fluorocytosine. Gastroenterology, 2000, 118, A529.	1.3	0
129	The HROC Collection and Matching Pairs of Colorectal Cancer Models (PDX and Cell Lines) from Primaries and Metastases. Gastroenterology, 2017, 152, S1279.	1.3	0
130	Accounting for randomness in measurement and sampling in studying cancer cell population dynamics. IET Systems Biology, 2014, 8, 230-241.	1.5	0
131	Abstract 2043: SATB1 (special AT-rich binding protein 1) as a putative therapeutic target in colorectal cancer. , 2015, , .		0
132	Abstract B24: Therapeutic response to bevacicumab, irinotecan, and temozolomide of PDX from human glioma cannot be correlated to common mutations as routinely identified by panel sequencing. , 2015, , .		0
133	Abstract 205: Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. , 2018, , .		0
134	Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer. , 2019, , .		0
135	Abstract A014: Gastric cancer PDX models for predictive preclinical studies: Establishment, drug sensitivity, and genomic characterization. , 2019, , .		0
136	Global Association of Cause-specific Mortality between the Major Gastrointestinal Cancers and Parkinsonâ€™s Disease for the First Two Decades of the New Millennium. , 2022, 13, 534.		0